Fundamental Data for AMLN

AMYLIN PHA(NSDQ:AMLN)

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN injection and BYETTA injection. Amylin''s research and development activities leverage the company''s expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is located in San Diego, California with over one thousand five hundred employees nationwide.

# Employees: 1800

Address: 9360 Towne Centre Drive,San Diego,CA,USA

Phone: 858-552-2200

Fax: 858-552-2212

Website: www.amylin.com

Email: IR@amylin.com

Sector: Medical

Industry: MED-BIOMED/GENE

Executive Officers

Joseph C. Cook Jr. (Chmn.)

Daniel M. Bradbury (Presi.; C.E.O.; Dir.)

Mark G. Foletta (Sr. V.P.; Fin.; C.F.O.)

Joe A. Young (Sr. V.P.; Mktg.)

Roger Marchetti (Sr. V.P.; Human Res.; Information Management,)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 9/30/2009

Next Earnings Date(Expected): 1/26/2010

Mean EPS (Next Qtr): ($0.25)

Mean EPS (Year): ($1.21)

Mean Estimate(Long Term): ($0.01)

P/E Ratio(Based on EPS estimate): -0.010

Number of Estimates: 13

Shares Performance

Period	AMLN	Compare to S&P
YTD	14.65 %	-5.11 %
4 Weeks	-3.19 %	-4.24 %
12 Weeks	-3.64 %	-9.15 %

Shares Information

Analyst Coverage: Y

Avg Volume: 2635540

Shares Outstanding: 141M

Market Cap: $1.76B

52 Week High: $15.38

52 Week Low: $6.05

P/E Ratio: -0.010

PEG Ratio: -0.010

Split: On 1/1/1990 AMLN split by factor of 0.250

Earnings Performance

EPS Growth in Last Quarter: 47.22 %

EPS Growth in Last Year: 58.70 %

Sales Growth in Last Quarter: 0.89 %

Sales Growth in Last Quarter: -3.26 %

Financials

Qtr Book Value: $3.80

Cash Flow/Share: ($0.01)

Change in Payout Ratio: -0.010

Price/Sales: 2.150